Ignite Creation Date:
2024-05-06 @ 1:57 PM
Last Modification Date:
2024-10-26 @ 1:22 PM
Study NCT ID:
NCT04173585
Status:
COMPLETED
Last Update Posted:
2023-03-27
First Post:
2019-11-20
Brief Title:
TEAM-Trial Targeting Epigenetic Therapy Resistance in AML With Bortezomib
Sponsor:
University Hospital Heidelberg
Organization:
University Hospital Heidelberg
Organization Data
Organization:
University Hospital Heidelberg
Class:
OTHER
Study ID:
NCT-2017-0530
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
University Hospital Heidelberg
Lead Sponsor Class:
OTHER
Responsible Party:
Prof Dr Richard F Schlenk
Responsible Party Title:
Scientific Coordinator
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
University Hospital Heidelberg
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| National Center for Tumor Diseases Heidelberg | OTHER |